Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Inspyr Therapeutics Inc (NSPX)

Inspyr Therapeutics Inc (NSPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,467
  • Shares Outstanding, K 543,152
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,300 K
  • 60-Month Beta -16.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NSPX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 11/19/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0018 +50.00%
on 10/01/21
0.0051 -47.06%
on 10/05/21
+0.0005 (+22.73%)
since 09/10/21
3-Month
0.0010 +170.00%
on 08/26/21
0.0088 -69.32%
on 08/02/21
-0.0039 (-59.09%)
since 07/09/21
52-Week
0.0010 +170.00%
on 08/26/21
0.0718 -96.24%
on 10/13/20
-0.0179 (-86.89%)
since 10/09/20

Most Recent Stories

More News
Inspyr Therapeutics Reports Financial Results and Business Update For Full Year 2020

- Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer - Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Further Strengthens Global Intellectual Property

WESTLAKE VILLAGE, CA / ACCESSWIRE / February 18, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline

- Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist - Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12,...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Strengthens Global Intellectual Property

- Expansion of patent portfolio of novel adenosine immuno-modulator compounds WESTLAKE VILLAGE, CA / ACCESSWIRE / December 10, 2020 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Reports 2020 Third Quarter Results and Business Update

- Implements New Corporate Strategy to Focus on Precision Therapeutics for the Treatment of Cancer - Strengthens Pipeline by Acquiring a Proprietary Portfolio of Novel Adenosine Immuno-Modulator Compounds...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Acquires a Novel Immuno-Onoclogy Precision Targeting Platform for the Treatment of Cancer

Preclinical data demonstrated delayed tumor growth, reduces metastases and anti-tumor immune response WESTLAKE VILLAGE, CA / ACCESSWIRE / October 9, 2020 / Inspyr Therapeutics, Inc. (OTC/PINK:NSPX), announces...

NSPX : 0.0027 (-18.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Inspyr Therapeutics, Inc. is a biotechnology company which focuses on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, and other cancers primarily in the United States. Its product candidates include Mipsagargin, G-115,...

See More

Key Turning Points

3rd Resistance Point 0.0040
2nd Resistance Point 0.0037
1st Resistance Point 0.0032
Last Price 0.0027
1st Support Level 0.0024
2nd Support Level 0.0021
3rd Support Level 0.0016

See More

52-Week High 0.0718
Fibonacci 61.8% 0.0448
Fibonacci 50% 0.0364
Fibonacci 38.2% 0.0280
Last Price 0.0027
52-Week Low 0.0010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar